(Q33739406)

29 July 2017

1 reference

title

Dopamine transporters and neuronal injury (English)

1 reference

29 July 2017

0 references

2

1 reference

29 July 2017

4

Caron MG

1 reference

29 July 2017

Miller GW

1

1 reference

PubMed ID

10498956

29 July 2017

Levey AI

series ordinal

3

1 reference

29 July 2017

1 October 1999

1 reference

Trends in Pharmacological Sciences

29 July 2017

1 reference

29 July 2017

20

1 reference

29 July 2017

10

1 reference

29 July 2017

424-429

1 reference

New insights into dopaminergic receptor function using antisense and genetically altered animals

29 July 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2899%2901379-6

7 January 2021

Cloning and expression of a functional serotonin transporter from rat brain

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2899%2901379-6

7 January 2021

Cloning and chromosomal mapping of the murine norepinephrine transporter.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2899%2901379-6

7 January 2021

Molecular characterization of the dopamine transporter.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2899%2901379-6

7 January 2021

Cloning and expression of a cocaine-sensitive dopamine transporter complementary DNA.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2899%2901379-6

7 January 2021

Expression cloning of a reserpine-sensitive vesicular monoamine transporter

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2899%2901379-6

7 January 2021

A cDNA that suppresses MPP+ toxicity encodes a vesicular amine transporter

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2899%2901379-6

7 January 2021

Vesicular neurotransmitter transporters: from bacteria to humans

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2899%2901379-6

7 January 2021

Gene transfer of a reserpine-sensitive mechanism of resistance to N-methyl-4-phenylpyridinium

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2899%2901379-6

7 January 2021

Differential expression of two vesicular monoamine transporters

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2899%2901379-6

7 January 2021

Distinct pharmacological properties and distribution in neurons and endocrine cells of two isoforms of the human vesicular monoamine transporter

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2899%2901379-6

7 January 2021

Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2899%2901379-6

7 January 2021

Protection against the dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine by monoamine oxidase inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2899%2901379-6

7 January 2021

Active uptake of MPP+, a metabolite of MPTP, by brain synaptosomes.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2899%2901379-6

7 January 2021

Parkinsonism-inducing neurotoxin, N-methyl-4-phenyl-1,2,3,6 -tetrahydropyridine: uptake of the metabolite N-methyl-4-phenylpyridine by dopamine neurons explains selective toxicity

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2899%2901379-6

7 January 2021

Dopamine transporter mRNA: dense expression in ventral midbrain neurons

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2899%2901379-6

7 January 2021

Dopamine transporter mRNA levels are high in midbrain neurons vulnerable to MPTP.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2899%2901379-6

7 January 2021

Dopamine transporter expression confers cytotoxicity to low doses of the parkinsonism-inducing neurotoxin 1-methyl-4-phenylpyridinium.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2899%2901379-6

7 January 2021

Parkinsonism-inducing neurotoxin MPP+: uptake and toxicity in nonneuronal COS cells expressing dopamine transporter cDNA

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2899%2901379-6

7 January 2021

Dopamine Neurotoxicity: Inhibition of Mitochondrial Respiration

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2899%2901379-6

7 January 2021

Reactive dopamine metabolites and neurotoxicity: implications for Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2899%2901379-6

7 January 2021

Subcellular compartmentalization of 1-methyl-4-phenylpyridinium with catecholamines in adrenal medullary chromaffin vesicles may explain the lack of toxicity to adrenal chromaffin cells

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2899%2901379-6

7 January 2021

Uptake of the neurotoxin, 4-methylphenylpyridinium, into chromaffin granules and synaptic vesicles: a proton gradient drives its uptake through monoamine transporter

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2899%2901379-6

7 January 2021

Selective MPP+ uptake into synaptic dopamine vesicles: possible involvement in MPTP neurotoxicity

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2899%2901379-6

7 January 2021

https://api.crossref.org/works/10.1016%2FS0165-6147%2899%2901379-6

1 reference

7 January 2021

Neural degeneration and the transport of neurotransmitters

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2899%2901379-6

7 January 2021

The neurotoxin 1-methyl-4-phenylpyridinium is sequestered within neurons that contain the vesicular monoamine transporter.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2899%2901379-6

7 January 2021

In brown Norway rats, MPP+ is accumulated in the nigrostriatal dopaminergic terminals but it is not neurotoxic: a model of natural resistance to MPTP toxicity.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2899%2901379-6

7 January 2021

The evolution of nigrostriatal neurochemical changes in the MPTP-treated squirrel monkey.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2899%2901379-6

7 January 2021

Generation of transporter-specific antibodies.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2899%2901379-6

7 January 2021

Immunochemical analysis of vesicular monoamine transporter (VMAT2) protein in Parkinson's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2899%2901379-6

7 January 2021

Hyperlocomotion and indifference to cocaine and amphetamine in mice lacking the dopamine transporter

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2899%2901379-6

7 January 2021

Profound neuronal plasticity in response to inactivation of the dopamine transporter

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2899%2901379-6

7 January 2021

Vesicular transport regulates monoamine storage and release but is not essential for amphetamine action.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2899%2901379-6

7 January 2021

Knockout of the vesicular monoamine transporter 2 gene results in neonatal death and supersensitivity to cocaine and amphetamine.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2899%2901379-6

7 January 2021

VMAT2 knockout mice: heterozygotes display reduced amphetamine-conditioned reward, enhanced amphetamine locomotion, and enhanced MPTP toxicity

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2899%2901379-6

7 January 2021

Dopamine transporter is required for in vivo MPTP neurotoxicity: evidence from mice lacking the transporter.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2899%2901379-6

7 January 2021

Increased MPTP neurotoxicity in vesicular monoamine transporter 2 heterozygote knockout mice.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2899%2901379-6

7 January 2021

Role of dopamine transporter in methamphetamine-induced neurotoxicity: evidence from mice lacking the transporter.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2899%2901379-6

7 January 2021

Increased methamphetamine neurotoxicity in heterozygous vesicular monoamine transporter 2 knock-out mice.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2899%2901379-6

7 January 2021

Cocaine receptors: in vivo labeling with 3H-(-)cocaine, 3H-WIN 35,065-2, and 3H-WIN 35,428

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2899%2901379-6

7 January 2021

Dopamine transporter immunoreactivity in rat brain

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2899%2901379-6

7 January 2021

The dopamine transporter: comparative ultrastructure of dopaminergic axons in limbic and motor compartments of the nucleus accumbens.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2899%2901379-6

7 January 2021

Immunochemical analysis of dopamine transporter protein in Parkinson's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2899%2901379-6

7 January 2021

The dopamine transporter: immunochemical characterization and localization in brain

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2899%2901379-6

7 January 2021

Dopamine transporter imaging with novel, selective cocaine analogs.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2899%2901379-6

7 January 2021

Rapid detection of Parkinson's disease by SPECT with altropane: a selective ligand for dopamine transporters

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2899%2901379-6

7 January 2021

[18F]CFT [(18F)WIN 35,428], a radioligand to study the dopamine transporter with PET: characterization in human subjects.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2899%2901379-6

7 January 2021

Presynaptic monoaminergic vesicles in Parkinson's disease and normal aging

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2899%2901379-6

7 January 2021

Parkinson disease in twins: an etiologic study

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2899%2901379-6

7 January 2021

The risk of Parkinson's disease with exposure to pesticides, farming, well water, and rural living

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2899%2901379-6

7 January 2021

Parkinson's disease and brain levels of organochlorine pesticides.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2899%2901379-6

7 January 2021

Perspectives on the discovery of central monoaminergic neurotransmission

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2899%2901379-6

7 January 2021

Direct sequencing of the reserpine-sensitive vesicular monoamine transporter complementary DNA in unipolar depression and manic depressive illness

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2899%2901379-6

7 January 2021

Striatal dopamine, dopamine transporter, and vesicular monoamine transporter in chronic cocaine users.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2899%2901379-6

7 January 2021

Striatal dopamine nerve terminal markers in human, chronic methamphetamine users

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2899%2901379-6

7 January 2021

Genotypic association between dopamine transporter gene polymorphisms and schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2899%2901379-6

7 January 2021

Abnormal dopamine uptake sites in postmortem striatum from patients with tourette's syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2899%2901379-6

7 January 2021

Abnormal structure of human striatal dopamine re-uptake sites in habitually violent alcoholic offenders: a fractal analysis.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2899%2901379-6

7 January 2021

Association of polymorphisms of dopamine D2 receptor (DRD2), and dopamine transporter (DAT1) genes with schizoid/avoidant behaviors (SAB).

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2899%2901379-6

7 January 2021

Association and linkage of the dopamine transporter gene and attention-deficit hyperactivity disorder in children: heterogeneity owing to diagnostic subtype and severity

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2899%2901379-6

7 January 2021

Confirmation of association between attention deficit hyperactivity disorder and a dopamine transporter polymorphism

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2899%2901379-6

7 January 2021

Role of serotonin in the paradoxical calming effect of psychostimulants on hyperactivity

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2899%2901379-6

7 January 2021

Developmentally regulated glycosylation of dopamine transporter.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2899%2901379-6

7 January 2021

Functional and anatomical evidence for different dopamine dynamics in the core and shell of the nucleus accumbens in slices of rat brain.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2899%2901379-6

7 January 2021

Lead, attention, and impulsive behavior: changes in a fixed-ratio waiting-for-reward paradigm.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2899%2901379-6

7 January 2021

Effects of lead on kinetics of 3H-dopamine uptake by rat brain synaptosomes.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2899%2901379-6

7 January 2021

10.1016/S0165-6147(99)01379-6

Identifiers

DOI

1 reference

29 July 2017

1 reference

PubMed ID

10498956